J&J Reports 77% Response Rate in HPV-Unrelated Head and Neck Cancer Group

The rate was 66% across all 29 evaluable participants. A randomized Phase 3 study will compare the regimen with pembrolizumab, platinum chemotherapy and 5-fluorouracil.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.